BRPI0919295A2 - 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios. - Google Patents

1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.

Info

Publication number: BRPI0919295A2
Authority: BR; Brazil
Prior art keywords: carboxamides; benzimidazole; inflammatory agents; inflammatory; agents
Prior art date: 2008-09-25

Application number

BRPI0919295A

Other languages

English (en)

Inventor

Dirk Stenkamp

Henning Priepke

Henri Doods

Juergen Mack

Kirsten Arndt

Klaus Klinder

Norbert Hauel

Raimund Kuelzer

Roland Pfau

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-25

Filing date

2009-09-25

Publication date

2015-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919295(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-25 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-12-15 Publication of BRPI0919295A2 publication Critical patent/BRPI0919295A2/pt

Links

FNLQDVXHDNFXIY-UHFFFAOYSA-N 3h-benzimidazole-5-carboxamide Chemical class NC(=O)C1=CC=C2NC=NC2=C1 FNLQDVXHDNFXIY-UHFFFAOYSA-N 0.000 title 1
229940121363 anti-inflammatory agent Drugs 0.000 title 1
239000002260 anti-inflammatory agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Virology (AREA)
Emergency Medicine (AREA)

BRPI0919295A 2008-09-25 2009-09-25 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios. BRPI0919295A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9998708P	2008-09-25	2008-09-25
EP08165120		2008-09-25
PCT/EP2009/062421 WO2010034796A1 (en)	2008-09-25	2009-09-25	1h-benz imidazole-5-carboxamides as anti-inflammatory agents

Publications (1)

Publication Number	Publication Date
BRPI0919295A2 true BRPI0919295A2 (pt)	2015-12-15

Family

ID=40344110

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
BRPI0919292A BRPI0919292A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
BRPI0919295A BRPI0919295A2 (pt)	2008-09-25	2009-09-25	1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
BRPI0919292A BRPI0919292A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios

Country Status (17)

Country	Link
US (4)	US8703796B2 (pt)
EP (4)	EP2334664A1 (pt)
JP (4)	JP5342646B2 (pt)
KR (4)	KR20110056530A (pt)
CN (4)	CN102164911A (pt)
AR (4)	AR073685A1 (pt)
AU (4)	AU2009295814A1 (pt)
BR (3)	BRPI0919738A2 (pt)
CA (4)	CA2737552A1 (pt)
IL (4)	IL211137A0 (pt)
MX (4)	MX2011002903A (pt)
NZ (4)	NZ591843A (pt)
RU (4)	RU2011116128A (pt)
TW (4)	TW201018684A (pt)
UY (1)	UY32138A (pt)
WO (4)	WO2010034798A1 (pt)
ZA (2)	ZA201101042B (pt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100250458A1 (en) *	2009-03-30	2010-09-30	Mspot, Inc.	Content based social networking system and method
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
EP3924343A1 (en) *	2008-09-26	2021-12-22	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
UY32470A (es) *	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
CN105853415A (zh) *	2009-05-12	2016-08-17	罗马克实验室有限公司	卤代烷基杂芳基苯甲酰胺化合物
MX391013B (es)	2009-06-26	2025-03-21	Romark Laboratories Lc	Compuestos y metodos para tratar influenza.
WO2011099832A2 (en) *	2010-02-12	2011-08-18	Crystalgenomics, Inc.	Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
US8759537B2 (en) *	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en)	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
TW201305178A (zh)	2010-10-29	2013-02-01	Glenmark Pharmaceuticals Sa	作為ｍＰＧＥＳ－１抑制物的三環化合物
UY33779A (es) *	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8486968B2 (en)	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds
US8466186B2 (en)	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds
AR084174A1 (es)	2010-12-21	2013-04-24	Lilly Co Eli	Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
WO2012102937A2 (en) *	2011-01-25	2012-08-02	Irm Llc	Compounds that expand hematopoietic stem cells
CA2826649C (en) *	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2495244A1 (en)	2011-03-02	2012-09-05	NovaSaid AB	Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
CA2834199C (en) *	2011-07-18	2020-01-07	Merck Patent Gmbh	Benzamides as allosteric modulators of the fsh receptor
WO2013038308A1 (en)	2011-09-15	2013-03-21	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
WO2013072825A1 (en)	2011-11-16	2013-05-23	Glenmark Pharmaceuticals S.A.	Phtalazinone derivatives as mpegs -1 inhibitors
WO2013118071A1 (en) *	2012-02-09	2013-08-15	Glenmark Pharmaceuticals S.A.	BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2013153535A1 (en)	2012-04-13	2013-10-17	Glenmark Pharmaceuticals S.A.	TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
CN103450329B (zh) *	2012-05-29	2015-05-27	首都医科大学	3h-咪唑并吡啶-6-甲酰氨基酸苄酯、其合成、抗肿瘤活性和应用
US9550737B2 (en)	2012-06-11	2017-01-24	Ucb Biopharma Sprl	TNF -α modulating benzimidazoles
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CN103922999B (zh) *	2013-01-16	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法及中间体化合物
US20140221335A1 (en) *	2013-02-06	2014-08-07	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104030977B (zh) *	2013-03-07	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法
WO2014167444A1 (en)	2013-04-08	2014-10-16	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
RU2673542C2 (ru) *	2013-06-25	2018-11-28	Ф. Хоффманн-Ля Рош Аг	Соединения для лечения спинальной мышечной атрофии
CN103435554A (zh) *	2013-09-06	2013-12-11	中国药科大学	2-苯氨基苯并咪唑类化合物及其用途
WO2015059618A1 (en)	2013-10-22	2015-04-30	Glenmark Pharmaceuticals S.A.	SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
PE20170143A1 (es)	2014-02-11	2017-03-19	Bayer Pharma AG	Benzimidazol-2-aminas como inhibidores de midh1
EP3105210B1 (en)	2014-02-11	2019-01-30	Bayer Pharma Aktiengesellschaft	Benzimidazol-2-amines as midh1 inhibitors
WO2015166398A1 (en) *	2014-04-30	2015-11-05	Aurigene Discovery Technologies Limited	3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
CN105294829B (zh) *	2014-06-13	2018-07-27	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性及应用
CN105198959B (zh) *	2014-06-13	2018-09-07	首都医科大学	咪唑并吡啶-6-甲酰-Met-Glu(OBzl)2,其合成,活性和应用
CN105198960B (zh) *	2014-06-13	2018-10-19	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105315335A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Gln-OBzl,其合成,活性和应用
CN105254709A (zh) *	2014-07-10	2016-01-20	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105315325A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Arg(NO2)-OBzl,其合成,活性和应用
PL3174535T3 (pl)	2014-08-01	2019-09-30	Glenmark Pharmaceuticals S.A.	Preparat nanocząstkowy zawierający inhibitor mpges-1
JP6645695B2 (ja) *	2014-10-14	2020-02-14	中尾　洋一	イミダゾピリジンアミン化合物、その製造方法及び用途
EP3209646B1 (en) *	2014-10-23	2020-07-22	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Benzimidazol-2-amines as midh1 inhibitors
US10137110B2 (en)	2014-10-23	2018-11-27	Bayer Pharma Aktiengesellschaft	1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
CN106146615B (zh) *	2015-03-23	2021-08-24	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性和应用
AU2016264958B2 (en)	2015-05-21	2020-10-29	Glaxosmithkline Intellectual Property Development Limited	Benzoimidazole derivatives as PAD4 inhibitors
EP3303302B1 (en)	2015-06-08	2019-03-20	Bayer Pharma Aktiengesellschaft	N-menthylbenzimidazoles as midh1 inhibitors
CN107698660B (zh) *	2015-06-23	2021-06-08	首都医科大学	咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用
JP6824954B2 (ja)	2015-07-16	2021-02-03	ドイチェスクレープスフォルシュングスツェントルムシュティフトゥングデスエッフェントリッヒェンレヒツ	ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール
EP3390387B1 (en)	2015-12-18	2021-11-17	Bayer Pharma Aktiengesellschaft	Heteroarylbenzimidazole compounds
WO2017207534A1 (en)	2016-06-03	2017-12-07	Bayer Pharma Aktiengesellschaft	Substituted heteroarylbenzimidazole compounds
JP7754623B2 (ja)	2017-11-22	2025-10-15	コンドリオンアイピービー．ブイ．	ｍＰＧＥＳ－１阻害剤としての化合物
CN110294751B (zh) *	2018-03-21	2020-11-20	湖南化工研究院有限公司	具生物活性的咪唑[4,5-b]并吡啶类化合物及其制备方法和应用
US12415816B2 (en)	2018-11-07	2025-09-16	Dana-Farber Cancer Institute, Inc.	Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en)	2018-11-07	2026-01-13	Dana-Farber Cancer Institute, Inc.	Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en)	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
MX2021015452A (es)	2019-06-25	2022-02-11	Gilead Sciences Inc	Proteinas de fusion flt3l-fc y metodos de uso.
GB201910608D0 (en) *	2019-07-24	2019-09-04	Enterprise Therapeutics Ltd	Compounds
MX2022004370A (es)	2019-10-18	2022-05-06	Forty Seven Inc	Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
WO2021087064A1 (en)	2019-10-31	2021-05-06	Forty Seven, Inc.	Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1抑制劑
MX2022006700A (es) *	2019-12-02	2022-09-02	Storm Therapeutics Ltd	Compuestos poliheterociclicos como inhibidores de mettl3.
JP7711068B2 (ja)	2019-12-24	2025-07-22	カルナバイオサイエンス株式会社	ジアシルグリセロールキナーゼ調節化合物
US20220402858A1 (en) *	2019-12-26	2022-12-22	Seika Corporation	Method for preparing diaminobiphenyl compound
CN115348862A (zh)	2020-01-20	2022-11-15	建新公司	用于复发型多发性硬化症(rms)的治疗性酪氨酸激酶抑制剂
IL295023A (en)	2020-02-14	2022-09-01	Jounce Therapeutics Inc	Antibodies and fusion proteins that bind to ccr8 and their uses
CR20220547A (es)	2020-05-01	2022-12-15	Gilead Sciences Inc	Compuestos de 2,4-dioxopirimidina inhibidores de cd73
TW202204350A (zh)	2020-05-06	2022-02-01	美商雅捷可斯治療公司	作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN114249694B (zh) *	2020-09-22	2025-06-17	浙江四维医药科技有限公司	一种特格拉赞中间体的制备方法
MX2023006854A (es)	2020-12-10	2023-07-20	Genzyme Corp	Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
US12043632B2 (en)	2020-12-23	2024-07-23	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh)	2021-05-18	2023-04-01	美商基利科學股份有限公司	使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
KR20240025616A (ko)	2021-06-23	2024-02-27	길리애드 사이언시즈, 인코포레이티드	다이아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en)	2021-06-23	2025-07-17	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
AU2022299051B2 (en)	2021-06-23	2025-03-13	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
KR20240005901A (ko)	2021-06-23	2024-01-12	길리애드 사이언시즈, 인코포레이티드	디아실글리세롤 키나제 조절 화합물
CA3235986A1 (en)	2021-10-29	2023-05-04	Gilead Science, Inc.	Cd73 compounds
WO2023086320A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	Forms and compositions of inhibitors of jak2
CA3234638A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4667056A1 (en)	2021-12-22	2025-12-24	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
EP4452414A2 (en)	2021-12-22	2024-10-30	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
LT4245756T (lt)	2022-03-17	2024-11-25	Gilead Sciences, Inc.	Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
AU2023240346A1 (en)	2022-03-24	2024-09-19	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh)	2022-04-05	2025-03-11	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
US20230374036A1 (en)	2022-04-21	2023-11-23	Gilead Sciences, Inc.	Kras g12d modulating compounds
IL317958A (en)	2022-07-01	2025-02-01	Gilead Sciences Inc	CD73 compounds
US20260042743A1 (en) *	2022-08-01	2026-02-12	Council Of Scientific And Industrial Research	Substituted benzimidazoles for treating viral diseases
WO2024064668A1 (en)	2022-09-21	2024-03-28	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en)	2022-12-22	2025-10-29	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
CN116332779B (zh) *	2023-03-13	2025-06-10	苏州敬业医药化工有限公司	一种3,4-二氨基苯甲酸甲酯的制备方法
JPWO2024190888A1 (pt) *	2023-03-16	2024-09-19
EP4695260A1 (en)	2023-04-11	2026-02-18	Gilead Sciences, Inc.	Kras modulating compounds
KR20250175331A (ko)	2023-04-21	2025-12-16	길리애드 사이언시즈, 인코포레이티드	Prmt5 억제제 및 이의 용도
AU2024306338A1 (en)	2023-06-30	2026-01-08	Gilead Sciences, Inc.	Kras modulating compounds
AU2024297978A1 (en)	2023-07-26	2026-02-05	Gilead Sciences, Inc.	Parp7 inhibitors
AU2024300557A1 (en)	2023-07-26	2026-02-05	Gilead Sciences, Inc.	Parp7 inhibitors
WO2025054530A1 (en)	2023-09-08	2025-03-13	Gilead Sciences, Inc.	Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en)	2023-09-08	2025-03-27	Gilead Sciences, Inc.	Kras g12d modulating compounds
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
WO2025245003A1 (en)	2024-05-21	2025-11-27	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2026039365A1 (en)	2024-08-12	2026-02-19	Gilead Sciences, Inc.	Kras modulating compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3006671A1 (de)	1980-02-22	1981-08-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel
FI91859C (fi)	1987-06-17	1994-08-25	Eisai Co Ltd	Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
JPH06759B2 (ja)	1989-09-22	1994-01-05	ファイザー製薬株式会社	新規なベンゾイミダゾール化合物
CN1323295A (zh)	1998-08-26	2001-11-21	阿文蒂斯药物有限公司	调节细胞粘着抑制作用的氮杂双环化合物
WO2000049005A1 (en)	1999-02-16	2000-08-24	Aventis Pharma Limited	Bicyclic compounds and their use as integrin receptor ligands
IL145748A0 (en)	1999-04-12	2002-07-25	Aventis Pharma Ltd	Substituted bicyclic heteroaryl compounds as integrin antagonists
CA2372840C (en) *	1999-05-05	2008-07-22	Aventis Pharma Limited	Substituted bicyclic compounds
US6340681B1 (en)	1999-07-16	2002-01-22	Pfizer Inc	2-benzimidazolylamine compounds as ORL-1-receptor agonists
ES2225231T3 (es) *	1999-10-06	2005-03-16	Boehringer Ingelheim Pharmaceuticals Inc.	Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas.
FR2833948B1 (fr) *	2001-12-21	2004-02-06	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
JP2005524668A (ja)	2002-03-01	2005-08-18	スミスクラインビーチャムコーポレーション	ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
US7071216B2 (en)	2002-03-29	2006-07-04	Chiron Corporation	Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US7037902B2 (en)	2002-07-03	2006-05-02	Receptron, Inc.	Affinity small molecules for the EPO receptor
JP4768265B2 (ja)	2002-10-15	2011-09-07	シンタファーマシューティカルズコーポレーション	新規化合物
CA2515215A1 (en)	2003-02-10	2004-08-26	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
FR2851563B1 (fr)	2003-02-26	2005-04-22	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7531553B2 (en)	2003-03-21	2009-05-12	Amgen Inc.	Heterocyclic compounds and methods of use
FR2852957B1 (fr)	2003-03-31	2005-06-10	Sod Conseils Rech Applic	Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US7329682B2 (en)	2003-04-03	2008-02-12	Ewha University-Industry Collaboration Foundation	Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
US7714009B2 (en)	2003-10-31	2010-05-11	Takeda Pharmaceutical Company Limited	Nitrogen-containing fused heterocyclic compounds
GB0401334D0 (en) *	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US7470712B2 (en) *	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
EP1778633B1 (en)	2004-06-18	2008-12-03	Biolipox AB	Indoles useful in the treatment of inflammation
US7521446B2 (en)	2005-01-13	2009-04-21	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) *	2005-01-13	2010-05-25	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
AU2005325497A1 (en) *	2005-01-19	2006-07-27	Biolipox Ab	Indoles useful in the treatment of inflammation
MX2007010404A (es)	2005-02-25	2008-01-11	Kudos Pharm Ltd	Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
CA2600570C (en)	2005-03-14	2011-12-06	Transtech Pharma, Inc.	Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors
WO2007059341A2 (en)	2005-11-16	2007-05-24	Sgx Pharmaceuticals, Inc.	Pyrazolothiazole protein kinase modulators
US7820821B2 (en)	2006-02-10	2010-10-26	Transtech Pharma, Inc.	Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
US20070287344A1 (en) *	2006-06-12	2007-12-13	Hiroshi Ohara	Fabric Construction Specifically For Damper
WO2008009924A2 (en)	2006-07-18	2008-01-24	Biolipox Ab	Indoles useful in the treatment of inflammation
KR20080027191A (ko)	2006-09-22	2008-03-26	이화여자대학교 산학협력단	신규한 벤즈옥사졸 유도체, 이의 제조방법 및 이를포함하는 약학 조성물
US20100004301A1 (en)	2006-12-14	2010-01-07	Benjamin Pelcman	Benzoxazoles Useful in the Treatment of Inflammation
WO2008129276A1 (en)	2007-04-19	2008-10-30	Boehringer Ingelheim International Gmbh	Disulfonamides useful in the treatment of inflammation
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es)	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) *	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en)	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
UY33779A (es)	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en)	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds
US8486968B2 (en)	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds

2009
- 2009-09-24 UY UY0001032138A patent/UY32138A/es not_active Application Discontinuation
- 2009-09-25 AR ARP090103704A patent/AR073685A1/es unknown
- 2009-09-25 CA CA2737552A patent/CA2737552A1/en not_active Abandoned
- 2009-09-25 EP EP09783403A patent/EP2334664A1/en not_active Withdrawn
- 2009-09-25 JP JP2011528332A patent/JP5342646B2/ja not_active Expired - Fee Related
- 2009-09-25 CA CA2738083A patent/CA2738083A1/en not_active Abandoned
- 2009-09-25 US US13/119,836 patent/US8703796B2/en not_active Expired - Fee Related
- 2009-09-25 US US13/119,834 patent/US8916599B2/en not_active Expired - Fee Related
- 2009-09-25 RU RU2011116128/04A patent/RU2011116128A/ru not_active Application Discontinuation
- 2009-09-25 BR BRPI0919738A patent/BRPI0919738A2/pt not_active IP Right Cessation
- 2009-09-25 JP JP2011528330A patent/JP5591807B2/ja not_active Expired - Fee Related
- 2009-09-25 AU AU2009295814A patent/AU2009295814A1/en not_active Abandoned
- 2009-09-25 WO PCT/EP2009/062424 patent/WO2010034798A1/en not_active Ceased
- 2009-09-25 CN CN2009801376052A patent/CN102164911A/zh active Pending
- 2009-09-25 KR KR1020117006845A patent/KR20110056530A/ko not_active Withdrawn
- 2009-09-25 NZ NZ591843A patent/NZ591843A/xx not_active IP Right Cessation
- 2009-09-25 NZ NZ591847A patent/NZ591847A/xx not_active IP Right Cessation
- 2009-09-25 TW TW098132581A patent/TW201018684A/zh unknown
- 2009-09-25 AU AU2009295813A patent/AU2009295813A1/en not_active Abandoned
- 2009-09-25 KR KR1020117006971A patent/KR20110056533A/ko not_active Withdrawn
- 2009-09-25 JP JP2011528333A patent/JP5342647B2/ja not_active Expired - Fee Related
- 2009-09-25 EP EP09783402A patent/EP2334652A1/en not_active Withdrawn
- 2009-09-25 MX MX2011002903A patent/MX2011002903A/es active IP Right Grant
- 2009-09-25 TW TW098132579A patent/TW201016696A/zh unknown
- 2009-09-25 US US13/119,832 patent/US8598190B2/en not_active Expired - Fee Related
- 2009-09-25 NZ NZ591845A patent/NZ591845A/xx not_active IP Right Cessation
- 2009-09-25 MX MX2011003152A patent/MX2011003152A/es active IP Right Grant
- 2009-09-25 CN CN2009801371627A patent/CN102164922A/zh active Pending
- 2009-09-25 NZ NZ591846A patent/NZ591846A/xx not_active IP Right Cessation
- 2009-09-25 BR BRPI0919292A patent/BRPI0919292A2/pt not_active IP Right Cessation
- 2009-09-25 EP EP09783405A patent/EP2361252A1/en not_active Withdrawn
- 2009-09-25 CN CN2009801376014A patent/CN102164924A/zh active Pending
- 2009-09-25 WO PCT/EP2009/062421 patent/WO2010034796A1/en not_active Ceased
- 2009-09-25 WO PCT/EP2009/062422 patent/WO2010034797A1/en not_active Ceased
- 2009-09-25 JP JP2011528331A patent/JP5591808B2/ja not_active Expired - Fee Related
- 2009-09-25 CA CA2737839A patent/CA2737839A1/en not_active Abandoned
- 2009-09-25 CN CN2009801469428A patent/CN102224143A/zh active Pending
- 2009-09-25 RU RU2011116129/04A patent/RU2011116129A/ru not_active Application Discontinuation
- 2009-09-25 BR BRPI0919295A patent/BRPI0919295A2/pt not_active IP Right Cessation
- 2009-09-25 MX MX2011003094A patent/MX2011003094A/es not_active Application Discontinuation
- 2009-09-25 EP EP09783406.3A patent/EP2350073B1/en not_active Not-in-force
- 2009-09-25 CA CA2737384A patent/CA2737384A1/en not_active Abandoned
- 2009-09-25 TW TW098132575A patent/TW201016682A/zh unknown
- 2009-09-25 KR KR1020117006846A patent/KR20110060910A/ko not_active Withdrawn
- 2009-09-25 AU AU2009295815A patent/AU2009295815A1/en not_active Abandoned
- 2009-09-25 AR ARP090103706A patent/AR073403A1/es unknown
- 2009-09-25 RU RU2011116133/04A patent/RU2011116133A/ru not_active Application Discontinuation
- 2009-09-25 AU AU2009295816A patent/AU2009295816A1/en not_active Abandoned
- 2009-09-25 KR KR1020117006974A patent/KR20110065478A/ko not_active Withdrawn
- 2009-09-25 AR ARP090103705A patent/AR073686A1/es unknown
- 2009-09-25 US US13/119,835 patent/US9040565B2/en not_active Expired - Fee Related
- 2009-09-25 WO PCT/EP2009/062425 patent/WO2010034799A1/en not_active Ceased
- 2009-09-25 RU RU2011116131/04A patent/RU2011116131A/ru not_active Application Discontinuation
- 2009-09-25 MX MX2011002948A patent/MX2011002948A/es active IP Right Grant
- 2009-09-25 TW TW098132551A patent/TW201018669A/zh unknown
- 2009-09-25 AR ARP090103703A patent/AR073684A1/es unknown
2011
- 2011-02-09 IL IL211137A patent/IL211137A0/en unknown
- 2011-02-09 IL IL211138A patent/IL211138A0/en unknown
- 2011-02-09 ZA ZA2011/01042A patent/ZA201101042B/en unknown
- 2011-02-09 ZA ZA2011/01041A patent/ZA201101041B/en unknown
- 2011-02-10 IL IL211147A patent/IL211147A0/en unknown
- 2011-02-10 IL IL211148A patent/IL211148A0/en unknown

Also Published As

Publication number	Publication date
IL211147A0 (en)	2011-04-28
IL211138A0 (en)	2011-04-28
CA2737552A1 (en)	2010-04-01
WO2010034796A1 (en)	2010-04-01
CN102164922A (zh)	2011-08-24
IL211137A0 (en)	2011-04-28
AU2009295816A1 (en)	2010-04-01
AR073403A1 (es)	2010-11-03
US20110312935A1 (en)	2011-12-22
CA2738083A1 (en)	2010-04-01
CN102164911A (zh)	2011-08-24
US8598190B2 (en)	2013-12-03
EP2350073A1 (en)	2011-08-03
US8703796B2 (en)	2014-04-22
NZ591846A (en)	2012-11-30
NZ591847A (en)	2013-01-25
US20120115902A1 (en)	2012-05-10
CN102164924A (zh)	2011-08-24
JP2012503627A (ja)	2012-02-09
WO2010034799A1 (en)	2010-04-01
KR20110056530A (ko)	2011-05-30
AU2009295814A1 (en)	2010-04-01
KR20110065478A (ko)	2011-06-15
JP2012503630A (ja)	2012-02-09
AU2009295815A1 (en)	2010-04-01
CN102224143A (zh)	2011-10-19
TW201018669A (en)	2010-05-16
US20110275656A1 (en)	2011-11-10
JP2012503628A (ja)	2012-02-09
RU2011116133A (ru)	2012-10-27
WO2010034797A1 (en)	2010-04-01
BRPI0919738A2 (pt)	2015-12-08
AR073684A1 (es)	2010-11-24
WO2010034798A1 (en)	2010-04-01
UY32138A (es)	2010-04-30
MX2011002948A (es)	2011-04-26
EP2361252A1 (en)	2011-08-31
KR20110056533A (ko)	2011-05-30
RU2011116131A (ru)	2012-10-27
BRPI0919292A2 (pt)	2017-05-30
JP5591807B2 (ja)	2014-09-17
CA2737839A1 (en)	2010-04-01
EP2334664A1 (en)	2011-06-22
ZA201101041B (en)	2011-10-26
TW201016682A (en)	2010-05-01
US9040565B2 (en)	2015-05-26
AU2009295813A1 (en)	2010-04-01
NZ591843A (en)	2012-09-28
TW201018684A (en)	2010-05-16
AR073686A1 (es)	2010-11-24
RU2011116129A (ru)	2012-10-27
EP2334652A1 (en)	2011-06-22
JP5342646B2 (ja)	2013-11-13
CA2737384A1 (en)	2010-04-01
IL211148A0 (en)	2011-04-28
ZA201101042B (en)	2011-10-26
US8916599B2 (en)	2014-12-23
MX2011003094A (es)	2011-04-26
MX2011002903A (es)	2011-04-11
NZ591845A (en)	2012-10-26
TW201016696A (en)	2010-05-01
EP2350073B1 (en)	2014-11-12
JP5591808B2 (ja)	2014-09-17
AR073685A1 (es)	2010-11-24
JP5342647B2 (ja)	2013-11-13
US20120122930A1 (en)	2012-05-17
MX2011003152A (es)	2011-04-27
KR20110060910A (ko)	2011-06-08
JP2012503629A (ja)	2012-02-09
RU2011116128A (ru)	2012-10-27

Legal Events

Date	Code	Title	Description
2016-06-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A E 6A ANUIDADES.
2016-09-27	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0919295A2 (pt)	2015-12-15	1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI1014956A2 (pt)	2018-07-24	agentes antinflamatórios.
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
BRPI1009315A2 (pt)	2016-03-08	agentes anti-inflamatórios
EP2288997A4 (en)	2012-02-15	DISTRIBUTED CACHE ARRANGEMENT
BRPI1010301A2 (pt)	2016-03-15	composição.
BRPI0913945A2 (pt)	2016-09-27	agentes anti-inflamatórios
BRPI0922845A2 (pt)	2015-12-29	pirazol-4-n-alcoxicarboxamidas como microbiocidas
BRPI0918430A2 (pt)	2015-11-24	4-fenil-1h-pirazóis inseticidas.
BRPI1008939A2 (pt)	2016-03-15	2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
BRPI0908116A2 (pt)	2015-10-06	pulverizador
DK2259989T3 (da)	2013-02-04	Rem
FIC20240018I1 (fi)	2024-06-04	Vamoroloni
UY33125A (es)	2011-07-29	Diaza-espiro-[5,5]-undecanos
EP2321062A4 (en)	2014-10-29	Sprayer
BRPI1011460A2 (pt)	2015-08-25	Composição desinfetante.
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
IT1396487B1 (it)	2012-12-14	Convogliatore.
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
BRPI0907863A2 (pt)	2019-09-24	pirrolopirimidinacarboxamidas
AT507449A3 (de)	2010-11-15	Dämmstoffbefestiger
BRPI0916990A2 (pt)	2015-07-28	Combinações inseticidas
PT2277578T (pt)	2019-10-25	Nebulizador.
EP2309529A4 (en)	2015-06-03	PHOTO CATHODE
DK2254963T3 (da)	2012-09-17	Kerne-skal-flowforbedrer